Post-Brexit Divergence Would Harm UK Industry

BGMA Director General Warwick Smith Talks Brexit Implications

On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.

Arrow_Flags_Pavement
Divergence from the European framework would harm industry and patients • Source: Shutterstock

More from Regulation

More from Policy & Regulation